zurück zur Startseite
Zentrale Tel.: 06221-560
Translational Lung Research Center Heidelberg

Pulmonary Hypertension

Pumonary hypertention (PH) is a disease of the pulmonary vasculature, which leads to shortness of breath, dizziness, fainting, and ultimately right heart failure. Five PH subclasses have been defined and all variants of PH together are estimated to affect about 100 million people worldwide. The vascular pathology of PH is characterized by pulmonary vasoconstriction and by abnormal (pseudo-malignant) remodeling of all vessel layers. Vascular smooth muscle cell (SMC) proliferation is a prominent feature in virtually all PH entities. 


Current PH therapy provides symptomatic relief and improves prognosis, but falls short as to the reestablishment of structural and functional lung vascular integrity, as a basis for symptom-free long-term survival. The restoration of physiological vascular structure and function (reverse modeling) represents major therapeutic goal of the DZL PH team.


Within the DZL PH research programm the TRLC research focuses on the analysis and exploitation of epigenetic mechanisms and signaling cascades underlying the beneficial effects of chronic exercise training in PH.


Research Groups

Grünig Group - this section is under developement

Select languageSelect language
Print Diese Seite per E-Mail weiterempfehlen